Transition in Low to Middle Income Countries • Building International Networks of Collaborating Partners • Identifying and sharing good practice within the hospitals and their communities IMHCN • Over 200 years ago societies decided to treat people with mental health problems in a very ...
1. Transplant candidates 2. Oncology patients 3. Known HTLV1 (HIV?) patients 4. Any subject with eosinophilia 5. Immigrants (with or without eosinophilia) 6. Any candidate for any reason to corticosteroids and/or immune suppressants (+ biologicals??) Is it justified, in these groups, to treat ...
P, Maina G, Pinna F, Vaggi M, Boggian I, Fontana M, Moro C, Carpiniello B. The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia. Neuropsychiatr Dis Treat. 2019 Apr 30;15:1045-1060. doi: 10.2147/NDT.S199048. PMID: 31118640; PMCID ...
(Trieste), Tiziana Bove (Udine), Mauro Giordano (Napoli) 15.25 How to better characterize LV systolic dysfunction? Do we need to treat LV systolic dysfunction, and if so, for which subgroups of patients and which treatment? Gianfranco Sinagra (Trieste) 15.40 How should fluid resuscitation be ...
supply of morphine so that obtaining refills is feasible for patients or families without requiring unreasonably frequent, expensive or arduous travel. Whenever clinically possible, oral morphine rather than the injectable form should be prescribed. All doctors should be trained to assess and treat ...
dosing Manjunath P. Pai 15.00 Vaccinating sepsis survivors Manu Shankar-Hari 15.15 Discussion QUESTIONS FOR THE EXPERTS PART 2 Chairmen: Michael Klompas, Giorgio Berlot, Tiziana Bove, Mauro Giordano, Savino Russo 15.25 How to better characterize LV systolic dysfunction? Do we need to treat LV ...
and statistical analyses for superiority trials will di" er from those investigating non-inferiority. The objectives are generally phrased using neutral word- ing (eg, “to compare the e" ect of treatment A versus treat- ment B on outcome X”) rather than in terms of a particular direction of e ...
’1,4% in prevenzione secondaria e solo dello 0,4% in prevenzione primaria. Di conseguenza, in prevenzione secondaria il numero di soggetti da trattare con statine (NNT o “number needed to treat” = 1/riduzione del rischio assoluto) utile ad evitare un evento cardiovascolare è minore che in preven- zione ...
-protocol” Efficacia pratica (effectiveness) “intention- to- treat” Definizioni delle popolazioni studiate ed efficacia Identificazione degli obiettivi Identificazione della popolazione target Reperimento delle risorse economiche Rigido criterio costo/beneficio Elevata copertura del target ...
dell’1,4% in prevenzione secondaria e solo dello 0,4% in prevenzione primaria. Di conseguenza, in prevenzione secondaria il numero di soggetti da trattare con statine (NNT o “number needed to treat” = 1/riduzione del rischio assoluto) utile ad evitare un evento cardiovascolare è minore che in ...
